Pharma Mar (PHM.MC) Hisse Fiyat
Pharma Mar Fiyat
Gelir, son 19 yılda yıllık bileşik %5,8 artarak 221,39 M EUR seviyesine ulaştı. Hisse başına kâr, son 13 yılda yıllık %21,2 büyüdü. Pharma Mar şirketinde net marj %33,9 seviyesinde bulunuyor; birkaç yıl önceki %40,4 seviyesine göre geriledi. Pharma Mar şu anda yaklaşık %1,38 temettü verimi sunuyor. Temettü dağıtım oranı, kârın yaklaşık %18 düzeyindedir. Temettü, son 18 yılda yıllık %15,5 artış gösterdi. Analistler 107,10 EUR medyan fiyat hedefi belirliyor; bu, güncel fiyatın %85,3 üzerinde bir seviyeye işaret ediyor. 13 analistten 9 tanesi hisse için alım öneriyor — genel konsensüs: Al.
Pharma Mar hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
Pharma Mar iş modeli ve hisse analizi
Pharma Mar hakkında sık sorulan sorular
The business model of Pharma Mar SA revolves around the research, development, and commercialization of innovative marine-derived pharmaceutical products. Pharma Mar specializes in the development of therapies derived from marine resources, particularly marine microorganisms. By harnessing the therapeutic potential of the sea, the company aims to bring effective treatments to patients suffering from various diseases, including cancer. With a focus on oncology, Pharma Mar seeks to address unmet medical needs and improve patients' lives globally. Through strategic partnerships, clinical trials, and ongoing research, Pharma Mar continues to drive advancements in the field of marine-derived pharmaceuticals.
Pharma Mar SA is primarily active in the pharmaceutical industry.
The main competitors of Pharma Mar SA in the market include other pharmaceutical companies operating in the same field and targeting similar market segments. Some notable competitors of Pharma Mar SA may include (examples only, not an exhaustive list): AstraZeneca, Novartis, Roche Holding, Pfizer, and Johnson & Johnson. These companies also focus on researching, developing, and marketing pharmaceutical products, including therapies and treatment options.
Pharma Mar SA is a leading biopharmaceutical company with a rich history and background. Established in 1986, the company is headquartered in Madrid, Spain. Pharma Mar SA focuses on the research, development, and commercialization of innovative marine-derived drugs to address various oncology and rare diseases. With a strong commitment to scientific excellence, Pharma Mar SA has built a diverse pipeline of potential therapies, leveraging the unique properties of marine organisms. The company has garnered global recognition for its breakthrough discovery of marine-derived compounds, including the development of Aplidin® (plitidepsin), a promising anticancer agent undergoing clinical trials. Pharma Mar SA continues to push boundaries in the pharmaceutical industry, striving to improve patients' lives worldwide.
Pharma Mar SA, a leading pharmaceutical company, has achieved significant milestones in its remarkable journey. The company's innovative approach and dedication to drug discovery have yielded remarkable results. Pharma Mar SA's milestones include successful clinical trials for their flagship drugs, receiving regulatory approvals, and securing strategic partnerships with renowned pharmaceutical companies. Furthermore, the company's consistent commitment to scientific research and development has resulted in groundbreaking discoveries that have revolutionized the treatment of various diseases. Through their remarkable achievements, Pharma Mar SA has solidified its position as a pioneering force in the pharmaceutical industry and continues to make invaluable contributions towards improving global healthcare.
Pharma Mar SA is primarily present in several countries and regions. The company has a strong presence in Spain, where it is based and operates its headquarters. Additionally, Pharma Mar SA has expanded its operations to various international markets, including the United States, Germany, Italy, France, and Switzerland. With a global presence, Pharma Mar SA strives to bring its innovative pharmaceutical products and treatments to patients worldwide.
Pharma Mar SA represents a set of core values and corporate philosophy that drive its operations. The company focuses on developing innovative therapies in the field of oncology and the treatment of other serious diseases. With a commitment to scientific excellence, Pharma Mar SA aims to create impactful solutions that improve patients' lives. Through strategic collaborations and continuous research, the company strives to deliver cutting-edge pharmaceutical products. Pharma Mar SA's dedication to ethical practices, transparency, and sustainability further reinforces its commitment to stakeholders and the global healthcare community.
Analistler şu anda Pharma Mar hissesi için ortalama 99,84 EUR hedef fiyat belirliyor (medyan: 107,10 EUR); bu, son fiyata göre +72,7 % anlamına gelir. Konsensüs 13 analist notuna dayanır.
13 analist şu anda Pharma Mar hissesini değerlendiriyor: 9 al, 3 tut, 1 sat öneriyor. 2026 için analistler Pharma Mar şirketinin 210,62 M EUR gelir ve 1,53 EUR hisse başına kâr üretmesini bekliyor.
Pharma Mar hissesi (PHM.MC) 7 borsada işlem görür, bunlar arasında: London (0RC6.L), Frankfurt (PMRA.F), München (PMRA.MU), Düsseldorf (PMRA.DU), Madrid (PHM.MC).
Pharma-Mar SA is a Spanish pharmaceutical company specializing in the development and marketing of cancer therapies. The company was founded in 1986 and is based in Colmenar Viejo, near Madrid. The company consists of two different business areas: Oncology and Consumer Healthcare. The Oncology division focuses on the development and marketing of innovative cancer drugs based on marine compounds, while the Consumer Healthcare division distributes over-the-counter drugs and cosmetic products. The company's business model is based on a strong research and development department that specializes in the exploration and development of cancer drugs based on marine compounds. They also collaborate with other pharmaceutical companies and research institutions to advance the research and development of cancer drugs. The company has a strong presence in international markets and has distribution partnerships in Europe, America, and Asia, allowing them to market their products worldwide and increase their revenue. Overall, Pharma-Mar SA is dedicated to the research, development, and distribution of cancer drugs, as well as over-the-counter drugs and cosmetic products.
beklenen'nin Pharma Mar hasılatı 210,62 M EUR'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Pharma Mar karı 26,34 M EUR'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Pharma Mar'nin Fiyat/Kazanç (F/K) oranı şu anda 37,76'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Pharma Mar hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Pharma Mar'nin Fiyat/Satış (F/S) oranı şu anda 4,72'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Pharma Mar hisse senedinin değerleme metriği olarak hizmet eder.
Pharma Mar'nin Eulerpool Kalite Puanı 3/10'dur.
Pharma Mar'nin ISIN'i ES0169501022'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Pharma Mar'nin WKN'i A2P9YT'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Pharma Mar'nin ticker'ı PHM.MC'dir. Ticker sembolü, Pharma Mar hisseleri borsada işlem görmek için kullanılır.
Pharma Mar Hissesi
Pharma Mar Emsaller Grubu
Pharma Mar Ticker
Pharma Mar FIGI
Pharma Mar'nin tüm temel göstergeleri ve derinlemesine analizi
Pharma Mar hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Pharma Mar şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: